Stalemate in Patent Dispute: Liquidia Reaches Settlement with United Therapeutics
Reading Time: 2 minutes
Legal peace achieved: Liquidia ends all patent disputes with United Therapeutics through a global settlement agreement. Market access secured: The supply of the dry powder formulation Yutrepia for PAH patients remains unrestricted. Indication removed: Liquidia withdraws its appeal and removes the indication for PH-ILD from the product information of Yutrepia. The US biopharmaceutical company Liquidia (LQDA) has reached a global settlement agreement with competitor United Therapeutics. The agreement concludes a years-long legal...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
